The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro

Int Immunol. 2007 Jun;19(6):785-99. doi: 10.1093/intimm/dxm047. Epub 2007 Jun 1.

Abstract

CD4+ CD25+ regulatory T cells (Tregs) have far-reaching immunotherapeutic applications, the realization of which will require a greater understanding of the factors influencing their function and phenotype during ex vivo manipulation. In murine models, IL-2 plays an important role in both the maintenance of a functional Treg population in vivo and the activation of suppression in vitro. We have found that IL-2 maintains optimal function of human CD4+ CD25+ Tregs in vitro and increases expression of both forkhead box protein 3, human nomenclature (FOXP3) and the distinctive markers CD25, cytotoxic T lymphocyte antigen-4 (CTLA-4) and glucocorticoid-induced tumor necrosis factor receptor superfamily member number 18 (GITR). Although IL-2 reduced spontaneous apoptosis of Tregs, this property alone could not account for the optimal maintenance of the regulatory phenotype. The inhibition of phosphatidylinositol 3-kinase (PI3K) signaling by LY294002, a chemical inhibitor of PI3K, abolished the maintenance of maximal suppressive potency by IL-2, yet had no effect on the up-regulation of FOXP3, CD25, CTLA-4 and GITR. Other common gamma chain (gammac) cytokines-IL-4, IL-7 and IL-15-had similar properties, although IL-4 showed a unique lack of effect on the expression of FOXP3 or Treg markers despite maintaining maximal regulatory function. Taken together, our data suggest a model in which the gammac cytokines IL-2, IL-4, IL-7 and IL-15 maintain the optimal regulatory function of human CD4+ CD25+ T cells in a PI3K-dependent manner, offering new insight into the effective manipulation of Tregs ex vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / metabolism
  • Antigens, Differentiation / metabolism
  • Apoptosis / drug effects
  • Blotting, Western
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / metabolism
  • CTLA-4 Antigen
  • Cell Proliferation / drug effects
  • Chromones / pharmacology
  • Coculture Techniques
  • Cyclosporine / pharmacology
  • Flow Cytometry
  • Forkhead Transcription Factors / metabolism
  • Glucocorticoid-Induced TNFR-Related Protein
  • HLA-DR Antigens / metabolism
  • Humans
  • Immune Tolerance / drug effects
  • Immune Tolerance / immunology
  • Interleukin-15 / pharmacology*
  • Interleukin-2 / pharmacology*
  • Interleukin-2 Receptor alpha Subunit / analysis*
  • Interleukin-2 Receptor alpha Subunit / metabolism
  • Interleukin-4 / pharmacology*
  • Interleukin-6 / pharmacology
  • Interleukin-7 / pharmacology*
  • Morpholines / pharmacology
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylation / drug effects
  • Proto-Oncogene Proteins c-akt / metabolism
  • Receptors, Antigen, T-Cell / antagonists & inhibitors
  • Receptors, Nerve Growth Factor / metabolism
  • Receptors, Tumor Necrosis Factor / metabolism
  • T-Lymphocytes, Regulatory / drug effects
  • T-Lymphocytes, Regulatory / metabolism*
  • T-Lymphocytes, Regulatory / physiology

Substances

  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Chromones
  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • Glucocorticoid-Induced TNFR-Related Protein
  • HLA-DR Antigens
  • Interleukin-15
  • Interleukin-2
  • Interleukin-2 Receptor alpha Subunit
  • Interleukin-6
  • Interleukin-7
  • Morpholines
  • Phosphoinositide-3 Kinase Inhibitors
  • Receptors, Antigen, T-Cell
  • Receptors, Nerve Growth Factor
  • Receptors, Tumor Necrosis Factor
  • TNFRSF18 protein, human
  • Interleukin-4
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Cyclosporine
  • Proto-Oncogene Proteins c-akt